lsoucek.bsky.social

lsoucek.bsky.social

@lsoucek.bsky.social

34 followers3 following25 posts

So proud to be part of @vhio.bsky.social's 20-year journey! ❤️ A place where science and clinical practice go hand in hand, with patients at the heart of everything we do. They are the reason why we do what we do! Here's to the next 20 years! 🎉 4you.vhio.net/en/2026/10/21/…

For years, #RAS and #MYC were considered "undruggable." The success of RAS has changed the conversation. Proud to see this recent @nature.com News & Views highlighting MYC as a promising next frontier and #Peptomyc as a key player helping advance the field. www.nature.com/articles/d41...

nature.comLandmark cancer trial shows success against ‘undruggable’ cancer — raising hopes for future treatmentsUnprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumours will be next.

Que suerte haber podido contar contigo, Erika, en mis primeros años organizando el nuevo lab en Barcelona. Siempre digo que no sé cómo lo hubiera hecho sin ti. Gracias por tu apoyo y buen humor. Ha sido un verdadero placer trabajar contigo. Te deseo toda la suerte del mundo!

This post is unavailable.

SF was home for 10 years, and UCSF is where I trained and grew as a scientist. Grateful to bridge academia and biotech, past and present. #MYC #OMO103 #Biotech #TranslationalResearch

lsoucek.bsky.social reposted

View full thread

In triple-negative breast cancer (TNBC), #Omomyc/#OMO-103 shuts down DNA-repair gene programs, triggers DNA damage and — in combination with PARP inhibitors — restores response even in PARPi-resistant models.

Honored to give the closing talk at the inaugural #GordonResearchConference (#GRC) on #Microproteins tomorrow in Castelldefels, Spain. Excited to share our latest work on developing a clinically viable MYC inhibitor and wrap up an incredible week of cutting-edge science. @vhio.bsky.social #peptomyc

We are delighted to share that our review “MYC in cancer: from undruggable target to clinical trials” is finally out in Nature Reviews Drug Discovery. What an amazing journey this has been and still promises to be! Big thanks to co-author Jonathan Whitfield. @vhio.bsky.social rdcu.be/eawOK

rdcu.beMYC in cancer: from undruggable target to clinical trialsNature Reviews Drug Discovery - Oncogene MYC has been considered ‘undruggable’ for many decades. This Review provides an overview of the various strategies to inhibit MYC, focusing on...

You are up to date.